Mental Health & Social Work
September 21, 2023
Dahye Ban, Jeongha Hwang
본 연구의 목적은 학생 정서·행동특성검사 상 관심군으로 선별된 고등학생들에게 마음챙김 기반 스트레스 감소(MBSR)프로그램을 적용하여 그 효과를 검증하고, 이들의 정서·행동문제에 대한 지속관리 개입 방안을 마련하는 것이다. 연구참여자는 학생 정서·행동특성검사 상 관심군으로 확인되어 2차 심층평가가 의뢰된 고등학생 중 본인과 보호자의 동의를 얻은 실험집단 남자 21명, 여자 16명 총 37명과 통제집단 남자 21명, 여자 12명 총 33명으로, 주 1회 매 50분 이상 총 8회기 프로그램을 진행하였다. 프로그램 효과성 검증을 위하여 실험-통제집단의 사전·사후 비교설계 모형을 설정하였고, 스트레스(PSS), 우울(CES-D), 마음챙김 척도, 정서조절양식 척도를 활용하여 효과성을 평가하였다. 프로그램 결과...
Pastoral Psychology
September 21, 2023
Alejandro Eros, Thomas G. Plante
4 citations
Abstract Contemplative practices have likely been used for self-awareness, concentration, creativity, and well-being since the dawn of time. While practices such as yoga and Buddhist meditation have been extensively studied in recent decades, Christian contemplative practices have received less attention in empirical research. This study aims to investigate the effects of centering prayer, a...
British Journal of Psychotherapy
September 19, 2023
Annie Pesskin
Georg Northoff is a philosopher, psychiatrist and neuroscientist working at the University of Ottawa in Canada. This, his most recent book, contributes to the now two-decade-old interdisciplinary attempt called neuropsychoanalysis to understand how neural activity in the brain transforms into psychic activity. Divided into nine chapters with titles inherently intriguing to psychoanalytic...
September 19, 2023
Maris Vainre, Tim Dalgleish, Peter Watson et al.
1 citation
preprint
Mindfulness-based programmes (MBPs) are increasingly offered in work settings, often in online self-guided format. However, the evidence on MBPs' effect on work performance (WP) is inconsistent.This pragmatic randomised controlled feasibility trial assessed procedural uncertainties, intervention acceptability and, preliminary effect sizes of a MBP on WP, relative to an alternative intervention,...
Biomolecules
September 19, 2023
Karolina Wydra, Kacper Witek, Agata Suder et al.
8 citations
BACKGROUND: Cocaine use disorder (CUD) is a relapsing brain disease caused by a chronic drug intake that involves neural mechanisms and psychological processes, including depression. Preclinical and clinical studies have demonstrated the promise of pharmacological drugs in controlling the reinstatement of cocaine by targeting the N-methyl-D-aspartate (NMDA) receptor. Recent evidence has...
Frontiers in Psychiatry
September 19, 2023
Hillary Jackson, Sara So, Abigail Yaffe et al.
87 citations
Introduction The classic psychedelic psilocybin, found in some mushroom species, has received renewed interest in clinical research, showing potential mental health benefits in preliminary trials. Naturalistic use of psilocybin outside of research settings has increased in recent years, though data on the public health impact of such use remain limited. Methods This prospective, longitudinal...
medRxiv
September 18, 2023
Rebecca Y. M. Cheung, Iris Yili Wang, Elsa Ngar Sze Lau
preprint
Abstract Guided by the theoretical processes of mindfulness and psychological well-being, this study examined serenity as a mediator between mindfulness facets and psychological well-being, as indexed by depressive symptoms and life satisfaction. Participants were 133 mindfulness practitioners who took part in a 3-day transnational meditation event in Hong Kong. Upon informed consent,...
The Journal of Thailand Nursing and Midwifery Council
September 15, 2023
กมลทิพย์ สงวนรัมย์, Владимир Судоргин, ณัฏฐ์พจน์ สาระวิถี
บทนำ การบำบัดโรคซึมเศร้าด้วยการเจริญสติตระหนักรู้ความคิดร่วมกับการรักษาด้วยยาต้านอาการซึมเศร้า มีผลลดอาการซึมเศร้าและช่วยป้องกันการกลับเป็นซ้ำของโรคซึมเศร้า ผู้บำบัดมีบทบาทสำคัญและจำเป็นต้องมีสมรรถนะในการถ่ายทอดกิจกรรมการบำบัด วัตถุประสงค์วิจัย เพื่อเปรียบเทียบความรู้เกี่ยวกับโรคซึมเศร้าและการบำบัด...
ACS Medicinal Chemistry Letters
September 15, 2023
Robert B. Kargbo
11 citations
Tryptamines, a class of 3-aminoethyl-indoles that activate the serotonin receptor, show potential for novel mental health treatments. The FDA has granted "breakthrough therapy designation" to psilocybin and MDMA for treatment-resistant depression, major depressive disorder, and post-traumatic stress disorder, sparking global research efforts. Various clinical trials are currently investigating...
ACS Medicinal Chemistry Letters
September 14, 2023
Marie Layzell, Peter Rands, Meghan Good et al.
6 citations
The psychedelic N,N- dimethyltryptamine (DMT) is in clinical development for the treatment of major depressive disorder. However, when administered via intravenous infusion, its effects are short-lived due to rapid clearance. Here we describe the synthesis of deuterated analogues of DMT with the aim of prolonging the half-life and decreasing the clearance rate while maintaining similar...